PHVS

Pharvaris NV

Sep 17 • 04:00PM ET

24.08

+0.27 1.13 %

Healthcare • Biotechnology • Netherlands • NASD

Peers: CRSP SRPT BPMC NTLA AKRO AVIR RNA EDIT QURE PBYI

| Held by: SCZ IEFA SBIO EWN ONEQ GWX BBC IEUS DBEZ

Index	-	P/E	-	EPS (ttm)	-3.37	Insider Own	62.79%	Shs Outstand	54.74M	Perf Week	3.57%
Market Cap	1.54B	Forward P/E	-	EPS next Y	-3.15	Insider Trans	0.00%	Shs Float	23.83M	Perf Month	8.66%
Enterprise Value	1.31B	PEG	-	EPS next Q	-0.79	Inst Own	28.28%	Short Float	1.70%	Perf Quarter	45.41%
Income	-183.26M	P/S	-	EPS this Y	-5.40%	Inst Trans	0.40%	Short Ratio	3.13	Perf Half Y	50.88%
Sales	0.00M	P/B	6.09	EPS next Y	-1.98%	ROA	-58.80%	Short Interest	0.40M	Perf YTD	25.61%
Book/sh	3.95	P/C	6.58	EPS next 5Y	7.91%	ROE	-63.96%	52W High	26.33 -8.55%	Perf Year	15.11%
Cash/sh	3.66	P/FCF	-	EPS past 3/5Y	-17.40% -7.73%	ROIC	-84.48%	52W Low	11.51 109.21%	Perf 3Y	156.17%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	3.25% 6.00%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-36.92%	Oper. Margin	-	ATR (14)	1.32	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.33	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	58.67	Recom	1.45
Dividend Gr. 3/5Y	- -	Current Ratio	8.33	EPS Q/Q	-58.98%	SMA20	4.28%	Beta	-2.80	Target Price	33.56
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	8.69%	Rel Volume	4.92	Prev Close	23.81
Employees	108	LT Debt/Eq	0.00	Earnings	Aug 12 AMC	SMA200	31.85%	Avg Volume	129.51K	Price	24.08
IPO	Feb 05, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	-10.73% -	Trades		Volume	637,756	Change	1.13%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-11-25	Initiated	Guggenheim	Buy	$32
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight	$28
Sep-25-23	Initiated	Wedbush	Outperform	$27
Aug-15-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$10 → $34
Oct-05-22	Initiated	Bryan Garnier	Buy	$16
Sep-13-22	Resumed	JMP Securities	Mkt Outperform	$34 → $18
Aug-23-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$40 → $10
Aug-22-22	Downgrade	BofA Securities	Neutral → Underperform	$26 → $13
May-25-22	Initiated	JMP Securities	Mkt Outperform	$34
Mar-02-21	Initiated	SVB Leerink	Outperform	$50
Mar-02-21	Initiated	Oppenheimer	Outperform	$48
Mar-02-21	Initiated	Morgan Stanley	Overweight	$51
Mar-02-21	Initiated	BofA Securities	Neutral	$41

Show Previous Ratings

Aug-12-25 04:05PM	Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-24-25 04:05PM	Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jul-22-25 09:22PM	Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire) -9.86%
04:05PM	Pharvaris Announces Proposed Public Offering of Ordinary Shares (GlobeNewswire)
Jul-10-25 06:50AM	Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025 (GlobeNewswire) +7.19%
06:50AM	Loading…
Jun-27-25 06:50AM	Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit (GlobeNewswire) -5.03%
Jun-16-25 06:50AM	Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress (GlobeNewswire)
Jun-10-25 06:50AM	Pharvaris Announces Annual Meeting of Shareholders (GlobeNewswire)
Jun-02-25 06:50AM	Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema (GlobeNewswire)
May-19-25 06:50AM	Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses (GlobeNewswire)
May-13-25 04:05PM	Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-12-25 06:50AM	Pharvaris to Host a Virtual R&D Call "Deucrictibant: Beyond HAE Type 1/2" on June 4 (GlobeNewswire)
Apr-07-25 06:58AM	Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -7.49%
Apr-02-25 06:30AM	EC grants orphan designation for Pharvaris' deucrictibant drug (Pharmaceutical Business Review)
Apr-01-25 06:50AM	Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission (GlobeNewswire) -5.54%
06:50AM	Loading…
Mar-03-25 06:50AM	Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress (GlobeNewswire)
06:48AM	Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025 (GlobeNewswire)
Jan-31-25 02:01PM	Why Pharvaris (PHVS) Is Advancing Today (Insider Monkey)
Jan-23-25 02:07AM	Why Is Andreas Halvorsen Bullish On Pharvaris N.V. (PHVS) Now? (Insider Monkey)
Jan-13-25 06:50AM	Pharvaris Outlines 2025 Strategic Priorities (GlobeNewswire) -7.81%
Dec-06-24 06:47AM	Pharvaris price target lowered to $46 from $50 at JMP Securities (TipRanks)
Nov-13-24 04:10PM	Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates (GlobeNewswire)
Nov-12-24 06:50AM	Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference (GlobeNewswire) -6.64%
Oct-30-24 06:00AM	Axonis Therapeutics Announces $115 Million Series A Financing (PR Newswire)
Oct-24-24 08:00AM	Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting (GlobeNewswire)
Oct-16-24 06:50AM	Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings (GlobeNewswire)
Oct-15-24 06:50AM	Pharvaris to Host Virtual Investor Event on October 23, 2024 (GlobeNewswire)
Oct-03-24 06:50AM	Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop (GlobeNewswire)
Sep-05-24 06:50AM	Pharvaris Provides Business Update and Expands Development Program for Deucrictibant (GlobeNewswire) +10.34%
06:49AM	Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024 (GlobeNewswire)
06:48AM	Loading…
06:48AM	Pharvaris Presents Data at the Bradykinin Symposium 2024 (GlobeNewswire)
Aug-28-24 06:50AM	Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium (GlobeNewswire)
Aug-14-24 06:50AM	Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -7.55%
Jul-16-24 04:02PM	Three Surprising Names That Could Be On Biogen's Buyout Shortlist (Investor's Business Daily)
11:55AM	Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense (Investor's Business Daily)
Jun-11-24 06:50AM	Pharvaris Announces Annual Meeting of Shareholders (GlobeNewswire)
Jun-04-24 06:50AM	Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses (GlobeNewswire) -5.31%
May-13-24 06:50AM	Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses (GlobeNewswire)
May-08-24 11:55PM	PHVS Stock Earnings: Pharvaris Misses EPS for Q1 2024 (InvestorPlace) -7.82%
04:10PM	Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-10-24 09:52PM	PHVS Stock Earnings: Pharvaris Misses EPS for Q4 2023 (InvestorPlace)
04:10PM	Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
04:08PM	Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer (GlobeNewswire)
Apr-04-24 06:50AM	Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference (GlobeNewswire)
Mar-18-24 06:50AM	Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses (GlobeNewswire) +6.34%
Mar-06-24 06:50AM	Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses (GlobeNewswire) +5.86%
Mar-05-24 06:50AM	Pharvaris to Participate in the Leerink Global Biopharma Conference 2024 (GlobeNewswire)
Feb-22-24 06:50AM	Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting (GlobeNewswire)
Feb-16-24 06:50AM	Pharvaris Announces Extraordinary Meeting of Shareholders (GlobeNewswire)
Jan-26-24 06:50AM	Pharvaris to Present at the WSAAI Annual Meeting 2024 (GlobeNewswire)
Jan-23-24 09:34AM	Pharvaris (PHVS) Up as FDA Lifts Clinical Hold on HAE Program (Zacks)
Jan-22-24 04:07PM	Top-Notch Pharvaris Eyes Profit-Taking Zone On A Key FDA Decision (Investor's Business Daily) +6.27%
07:34AM	FDA lifts remaining hold on Pharvaris' HAE drug, clearing path to phase 3 (FierceBiotech.com)
06:50AM	Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks (GlobeNewswire)
Jan-05-24 06:50AM	Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities (GlobeNewswire)
Dec-08-23 06:00PM	Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA LEN UCARE Conference 2023 (GlobeNewswire)
Dec-07-23 03:17PM	Pharvaris (PHVS) Stock Up 18% on HAE Drug Meeting Study Goal (Zacks)
Dec-06-23 10:16AM	Why Is Pharvaris (PHVS) Stock Up 36% Today? (InvestorPlace) +18.14%
09:33AM	Pharvaris' oral hereditary angioedema med slashes attacks in turnaround post-FDA hold (FierceBiotech.com)
07:02AM	Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded Warrants (GlobeNewswire)
06:56AM	Pharvaris shares spike as drug appears to prevent symptoms of rare disorder (BioPharma Dive)
06:50AM	Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks (GlobeNewswire)
Nov-30-23 06:50AM	Pharvaris to Present at the GA LEN UCARE Conference 2023 (GlobeNewswire)
Nov-15-23 06:50AM	Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer (GlobeNewswire) -11.49%
Nov-09-23 11:00AM	Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting (GlobeNewswire)
Nov-02-23 06:50AM	Pharvaris Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-30-23 06:50AM	Pharvaris To Present at the ACAAI 2023 Annual Scientific Meeting (GlobeNewswire)
Oct-13-23 06:50AM	Pharvaris To Present at the APAAACI 2023 International Conference (GlobeNewswire)
Oct-04-23 07:34AM	Pharvaris To Present at the CIIC Fall 2023 Conference (GlobeNewswire)
Sep-19-23 06:50AM	Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference (GlobeNewswire) +16.68%
Sep-06-23 06:51AM	Pharvaris To Present at the 18th German Allergy Congress (GlobeNewswire)
06:50AM	Pharvaris To Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-31-23 08:09PM	Expect at Least 60% Upside, Says Morgan Stanley About These 2 Buy-Rated Stocks (TipRanks)
Aug-23-23 06:50AM	Pharvaris To Present at the 2023 HAEi Regional Conference EMEA (GlobeNewswire)
Aug-15-23 09:59AM	Redfin upgraded, CSSE downgraded: Wall Street's top analyst calls (The Fly) +8.58%
Aug-07-23 06:50AM	Pharvaris Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -6.91%
Jul-21-23 10:20AM	Pharvaris Presents Clinical Data at the 2023 U.S. HAEA National Summit (GlobeNewswire)
Jul-03-23 08:16AM	Pharvaris N.V.'s (NASDAQ:PHVS) largest shareholders are private equity firms with 50% ownership, institutions own 18% (Simply Wall St.)
Jun-27-23 12:11PM	Why Shares of Pharvaris N.V. Are Up Tuesday (Motley Fool) +7.96%
Jun-26-23 02:27PM	FDA Removes Clinical Hold Of Pharvaris' Deucrictibant For On-Demand Treatment Of HAE (Benzinga) +27.76%
06:50AM	Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE (GlobeNewswire)
Jun-20-23 06:50AM	Pharvaris Announces $70 Million Private Placement Financing (GlobeNewswire)
Jun-10-23 06:01PM	Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023 (GlobeNewswire)
Jun-01-23 06:50AM	Pharvaris Announces Annual Meeting of Shareholders (GlobeNewswire) +5.12%
May-17-23 09:55AM	Wall Street Analysts Predict an 88.24% Upside in Pharvaris N.V. (PHVS): Here's What You Should Know (Zacks)
May-08-23 06:50AM	Pharvaris Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-06-23 01:00PM	Deucrictibant Data Highlighted in Multiple Presentations at the C1-Inhibitor Deficiency and Angioedema Workshop (GlobeNewswire)
Apr-05-23 06:51AM	Pharvaris Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-20-23 03:31PM	We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth (Simply Wall St.) -5.11%
Mar-18-23 12:35AM	Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks Highlighted at the 2023 HAEi Regional Conference APAC (GlobeNewswire)
Mar-02-23 06:50AM	Pharvaris to Present in Upcoming March Investor Conferences (GlobeNewswire) +8.51%
Feb-24-23 06:50AM	Pharvaris to Highlight Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks at AAAAI Annual Meeting (GlobeNewswire) -9.25%
Feb-08-23 06:50AM	Pharvaris to Present at SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-24-23 05:36AM	Pharvaris N.V.'s (NASDAQ:PHVS) largest shareholders are private equity firms with 44% ownership, institutions own 26% (Simply Wall St.) +6.42%
Jan-09-23 06:50AM	Pharvaris Provides Regulatory, Clinical, and Corporate Updates (GlobeNewswire)
Dec-08-22 01:15PM	Pharvaris Shares Surges On Positive Data From HAE Attacks Study, Makes Way For FDA To Remove Clinical Hold (Benzinga) +356.57%
06:51AM	Pharvaris Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
06:50AM	Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks (GlobeNewswire)
Nov-10-22 08:00AM	Pharvaris to Present PHVS416 and PHVS719 Clinical Data for Treatment of HAE at the ACAAI Annual Scientific Meeting 2022 (GlobeNewswire) -10.32%
Oct-11-22 02:27PM	We're Hopeful That Pharvaris (NASDAQ:PHVS) Will Use Its Cash Wisely (Simply Wall St.) -5.48%

Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Johannes Gerardus Christiaan Petrus Schikan, and Anne Lesage on September 30, 2015 and is headquartered in Leiden, the Netherlands.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	SEC Form 4
PENG LU	Officer	Jul 14 '25	Proposed Sale	25.12	11,307	284,032	Jul 14 04:22 PM
PENG LU	Officer	Jul 11 '25	Proposed Sale	19.83	351	6,960	Jul 11 04:21 PM
MORGAN CONN	Officer	Dec 02 '24	Proposed Sale	19.69	26,562	522,937	Dec 02 04:27 PM
PENG LU	Officer	Oct 31 '24	Proposed Sale	24.80	15,000	372,000	Oct 31 04:27 PM
PENG LU	Officer	Oct 24 '24	Proposed Sale	22.21	17,000	377,570	Oct 24 04:23 PM
ROBERT R. GLASSMAN	Director	Sep 20 '24	Proposed Sale	20.01	3,007	60,172	Sep 20 04:27 PM
JOHANNES GER. CHRIS. PE SCHIKA	Officer	Sep 19 '24	Proposed Sale	19.15	70,000	1,340,500	Sep 19 06:45 PM
SCHOODIC MANAGEMENT BV	Officer	Sep 19 '24	Proposed Sale	19.15	200,000	3,830,000	Sep 19 06:45 PM
ANNE SIMONNE J. LESAGE	Officer	Sep 19 '24	Proposed Sale	19.15	110,000	2,106,500	Sep 19 06:44 PM
PENG LU	Officer	Sep 19 '24	Proposed Sale	20.26	13,615	275,840	Sep 19 04:27 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PHVS

Pharvaris NV

Upgrade your FINVIZ experience